Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. It blocks viral entry into host cells while preserving normal immunologic function. The Company is also investigating an intramuscular method of administration of Trogarzo. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy.

TSX:TH - Post by User

Theratechnologies Inc > TH1902 ClinicalTrials.gov Update

<< Previous

Bullboard Posts

Next >>

Comment by jfm1330on Jan 29, 2023 12:28pm

125 Views

Post# 35252729

RE:RE:RE:RE:TH1902 ClinicalTrials.gov Update

The strange one is Windtree Therapeutics. The three other ones are related to clinical trials.

Wino115 wrote: One looks like a fairly standard CRO but some of the others seem to have no purpose whatsoever in a geneticaly targeted cancer drug trial. It almost appears to be a mistake listing the Montreal dermatological one and the first one, which has it's own drugs in trial and is not a CRO. Perhaps this is some kind of clerical error by the website or something. Very odd and for such a small trial you definitely wouldn't need more than one CRO. I'm guessing that specific collab info is not accurate.

scarlet1967 wrote:

They don't need more than one CRO yet most of these companies provide CRO services?? Different opinions?
Also they have removed THTX as the point of contact?? Partners? What is the company up to?
https://clinicaltrials.gov/ct2/history/NCT04706962?A=6&B=7&C=merged#StudyPageTop

SPCEO1 wrote: They also added "Sort1+ cancers" to the list of conditions being studied, so a broader scope.

Other than the collaborators, who may have been in place all along and were just added for completeness now, there were no significant changes. The fact they did not change the end date of the study of 3/23 may be a bit ominous, though. Clearly, the study will take longer if it restarts.I imagine they cannot put a new end date in until they actually know what the new study approach entails. So, maybe it is not r eally all that ominous.

SABBOBCAT wrote:
Looks like they finally updated the clinicaltrials.gov listing yesterday. There was an interesting tidbit in the collaborators section. It now lists altasciences, Windtree Therapeutics, Syneos Health, and Innovaderm Research Inc.

Perhaps some the more scientifically minded posters here can spool up some interesting theories as to what these relationships could be. Some of them are CRO based, but what stands out to me is some are specializing in dermatology and cardiovascular therapies.